153 related articles for article (PubMed ID: 26782712)
1. Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study.
Moreira DM; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):180-4. PubMed ID: 26782712
[TBL] [Abstract][Full Text] [Related]
2. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study.
Moreira DM; Nickel JC; Gerber L; Muller RL; Andriole GL; Castro-Santamaria R; Freedland SJ
Cancer; 2014 Jan; 120(2):190-6. PubMed ID: 24323568
[TBL] [Abstract][Full Text] [Related]
3. The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens.
Moreira DM; de O Freitas DM; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):413-417. PubMed ID: 28585572
[TBL] [Abstract][Full Text] [Related]
4. Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study.
Moreira DM; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ
Prostate; 2015 Sep; 75(13):1492-8. PubMed ID: 26184556
[TBL] [Abstract][Full Text] [Related]
5. Extent of Baseline Prostate Atrophy Is Associated With Lower Incidence of Low- and High-grade Prostate Cancer on Repeat Biopsy.
Freitas DM; Andriole GL; Castro-Santamaria R; Freedland SJ; Moreira DM
Urology; 2017 May; 103():161-166. PubMed ID: 28024967
[TBL] [Abstract][Full Text] [Related]
6. Baseline prostate atrophy is associated with lower tumor volume in men with prostate cancer on repeat biopsy.
Moreira DM; Andriole GL; Castro-Santamaria R; Freedland SJ
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):106-112. PubMed ID: 29203895
[TBL] [Abstract][Full Text] [Related]
7. Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.
Freitas D; Andriole GL; Freedland SJ; Neto BS; Moreira DM
Urology; 2019 Jul; 129():160-164. PubMed ID: 30914334
[TBL] [Abstract][Full Text] [Related]
8. Both acute and chronic inflammation are associated with less perineural invasion in men with prostate cancer on repeat biopsy.
Kuang AG; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ; Moreira DM
BJU Int; 2019 Jan; 123(1):91-97. PubMed ID: 29873889
[TBL] [Abstract][Full Text] [Related]
9. Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
Moreira DM; Bostwick DG; Andriole GL; Peterson BL; Cohen HJ; Castro-Santamaria R; Freedland SJ
J Urol; 2015 Nov; 194(5):1241-6. PubMed ID: 26165588
[TBL] [Abstract][Full Text] [Related]
10. Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study.
Naha U; Nickel JC; Andriole GL; Freedland SJ; Moreira DM
J Urol; 2021 Mar; 205(3):755-760. PubMed ID: 33080149
[TBL] [Abstract][Full Text] [Related]
11. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
12. Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy.
Karakiewicz PI; Benayoun S; Bégin LR; Duclos A; Valiquette L; McCormack M; Bénard F; Saad F; Perrotte P
Int J Clin Pract; 2007 Mar; 61(3):425-30. PubMed ID: 17313610
[TBL] [Abstract][Full Text] [Related]
13. Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy.
Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Mariotto A; Brunelli M; Cerruto MA; Cacciamani GE; Migliorini F; Siracusano S; Artibani W
World J Urol; 2020 Apr; 38(4):957-964. PubMed ID: 31154465
[TBL] [Abstract][Full Text] [Related]
14. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
15. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
[TBL] [Abstract][Full Text] [Related]
16. Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.
Ploussard G; Nicolaiew N; Marchand C; Terry S; Allory Y; Vacherot F; Abbou CC; Salomon L; de la Taille A
BJU Int; 2013 May; 111(6):988-96. PubMed ID: 23452046
[TBL] [Abstract][Full Text] [Related]
17. Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial.
Allott EH; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
Cancer Prev Res (Phila); 2017 Jun; 10(6):319-326. PubMed ID: 28487295
[TBL] [Abstract][Full Text] [Related]
18. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
[TBL] [Abstract][Full Text] [Related]
19. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
20. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
